Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
America’s much-maligned vaccine rollout is actually going relatively well, at least compared to other wealthy countries.
The big picture: The U.S. has carried out more vaccinations than any country in the world, and given a first dose to a higher percentage of its population (12%) than all but five countries: Israel, the Seychelles, the UAE, the U.K. and Bahrain.
- In fact, the U.S. is distributing doses three times as quickly as the EU, adjusted for population, and nearly five times as quickly as Canada.
The backstory: The U.S. has some major advantages over most of the world. Not only does America have the money to reserve more doses than it could possibly use, it also has the capacity to manufacture them domestically.
- Canada’s slow rollout and the recent dispute over doses between the EU and U.K. have underlined the difficulties of relying on imports.
- The U.S. also made massive bulk purchases early — through the Trump administration’s Operation Warp Speed — and thus ramped up production capacity while securing its spot at the front of the line.
- The EU moved more slowly both in securing contracts and in approving vaccines, and has paid a price. Israel, by contrast, paid a premium and promised valuable data to get Pfizer’s vaccine early.
- It also helps that the two most effective vaccines on the market were developed entirely (Moderna) or partially (Pfizer/BioNTech) in the U.S.
Between the lines: Despite crumbling infrastructure and chaotic politics, the U.S. remains a scientific, technological and manufacturing powerhouse. That has played to its advantage, as has the sense of urgency with which the U.S. approached the vaccination challenge.
- Some wealthy countries that haven't been hit as hard by the pandemic, like Japan and South Korea, have been much slower to administer vaccines.
Yes, but: The U.S. has secured world-leading vaccine supplies, but been somewhat less successful at translating them into actual vaccinations.
- The most impressive rollouts have tended to come in countries with modern, centralized public health care infrastructure, making it easier to identify who's eligible for vaccinations and where to administer them. America's approach has at times appeared clunky by comparison.
- President Biden has accused his predecessor of failing to develop a national distribution strategy, and promised to ramp things up quickly.
What to watch: If Biden's plan to vaccinate every willing American by July comes to fruition, the U.S. will likely be far ahead of nearly every other large country, including China.
- The challenge could fairly quickly turn to helping distribute vaccines around the world.
The bottom line: America’s vaccine rollout has been imperfect, unequal, and at times deeply frustrating. But look around the world and it’s clear that it could be going a whole lot worse.
Go deeper: